Tandem sees big debut for super-slim insulin pump; Respiratory Motion gets FDA nod for monitor;

@FierceMedDev: Check out our rundown of the year's biggest announced layoffs in the medical device world. More | Follow @FierceMedDev

@MarkHFierce: BD's CFO is leaving to pursue an "entrepreneurial opportunity." More | Follow @MarkHFierce

@DamianFierce: Biomet reduced its quarterly losses thanks to its $280M buy of DePuy's trauma unit. More | Follow @DamianFierce

Respiratory Motion won 510(k) clearance for a new respiratory monitoring system designed to provide continuous, noninvasive minute ventilation data in non-ventilated patients. Release

Tandem Diabetes Care is making an iPhone-like early market impression with its new t:slim insulin delivery system, the first FDA-cleared touch-screen insulin pump. Story

Sen. Dan Coates (R-IN) says November's presidential election is the public's only chance to do away with the medical device tax, as Mitt Romney has promised to repeal the Affordable Care Act. Editorial

Scientists will meet in Dublin later this month for a conference designed to share advances in biomaterials research and innovation that could improve device performance. Item

Danaher is making good on its plans to grow the company's medical diagnostics presence and shed other business lines. The company and partner Cooper will sell their hand and power tools joint venture to Bain Capital for $1.6 billion. Story

Focus Diagnostics got 510(k) clearance for its RNA test for influenza, co-developed with 3M. News (reg. req.)

TransMedics' Organ Care System allows lung transplants to be stored at body temperature, keeping them in better condition than if they had been cooled down during transport. Article

The New York Times explores how iPhone and iPad apps are redefining medical devices specifically, and medicine in general. Story (sub.req.)

Biotech News

@FierceBiotech: Diamyd Medical sells off nerve-targeted delivery unit. More | Follow @FierceBiotech

@JohnCFierce: I'd like to see Lilly file an NDA on sola, see how regulators handle secondary analysis on data from 1 trial that couldn't be confirmed in 2nd. | Follow @JohnCFierce

@RyanMFierce: Top counterfeit drug events in 2012 report, shows this problem affects all of us. More | Follow @RyanMFierce

MedImmune partners on trials for a new slate of cancer immunotherapy combos. Article

Oxford Bio shares tumble after mid-stage cancer study fizzles out. News

Pharma News

@FiercePharma: Will Optimer's plan to boost Dificid sales work? It's a volume-pricing move. More | Follow @FiercePharma

No breakup for J&J? Goldman analyst says 'Sell'. Story

Pfizer wraps up Celebrex suit in $164M settlement. News

Drug Delivery News

NuPathe axes half its workforce, sells $28M of securities. Article

Dissolving microneedles hit the sweet spot in diabetes. Item

Diamyd Medical sells off nerve-targeted delivery unit. Story

Smaller electric pulse hits the spot for DNA vaccines. Report

Biomarkers News

Scratching a genetic itch in atopic dermatitis. More

Biomarker panel spots the risk of Type 2 diabetes. Report

Making a GENIE-us connection: Linking genes with diabetic kidney disease. Story

Prostate cancer genetic barcodes predict aggressiveness. Article